U.S. markets open in 3 hours 14 minutes
  • S&P Futures

    4,462.50
    -11.75 (-0.26%)
     
  • Dow Futures

    34,681.00
    -68.00 (-0.20%)
     
  • Nasdaq Futures

    15,487.25
    -30.50 (-0.20%)
     
  • Russell 2000 Futures

    2,219.40
    -8.50 (-0.38%)
     
  • Crude Oil

    71.98
    -0.63 (-0.87%)
     
  • Gold

    1,765.90
    +9.20 (+0.52%)
     
  • Silver

    23.09
    +0.30 (+1.30%)
     
  • EUR/USD

    1.1786
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    19.13
    +0.95 (+5.23%)
     
  • GBP/USD

    1.3784
    -0.0012 (-0.09%)
     
  • USD/JPY

    109.9860
    +0.2680 (+0.24%)
     
  • BTC-USD

    47,695.01
    -285.83 (-0.60%)
     
  • CMC Crypto 200

    1,215.90
    -17.39 (-1.41%)
     
  • FTSE 100

    7,022.14
    -5.34 (-0.08%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation.

“We are pleased that the FDA has granted Fast Track Designation for PR001, which underscores the unmet need of patients with Parkinson’s disease with a GBA1 mutation, a chronic and progressive neurodegenerative disorder that comprises 7% to 10% of the total Parkinson’s disease population worldwide,” said CEO Asa Abeliovich.

“With no treatments available that modify the progressive course or the underlying disease process of Parkinson’s disease, a potential disease-modifying therapy like PR001 could significantly transform the lives of patients with this disease.”

Prevail Therapeutics shares traded higher by 6.5% to $11.20 at time of publication. The stock has a 52-week high of $16.90 and a 52-week low of $9.83.

Related Links:

Prevail Therapeutics Opens Below IPO Price

Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.